Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KUP-101A in Advanced Solid Tumors
NCT07600476Phase 1Recruiting
- Sponsor
- Kupando
- Start
- Jul 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of KUP101 in melanoma, squamous cell carcinoma (SCC), Merkel cell carcinoma (MCC) and 1 more (7 arms), sponsored by Kupando. Primary endpoints: Treatment-Emergent Adverse Events at 3 months, Dose-Limiting Toxicities at 1 week and 2 more. Started Jul 2026; status: recruiting.
02
Drugs
KUP101
03
Conditions
melanomasquamous cell carcinoma (SCC)Merkel cell carcinoma (MCC)basal cell carcinoma (BCC)
Beyond the preview
Go deeper on NCT07600476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07600476.